Key result
Long-term prophylaxis for rare inherited coagulation factor deficiencies, which have an aggregate prevalence of approximately 1:100,000, is reviewed to provide clinical recommendations.
Why the study?
Does long-term prophylaxis prevent recurrent haemorrhage in patients with rare inherited coagulation factor deficiencies?
Does long-term prophylaxis prevent recurrent haemorrhage in patients with rare inherited coagulation factor deficiencies?
This review summarizes the available literature and provides recommendations on long-term prophylaxis for rare inherited coagulation factor deficiencies.
Prophylaxis in rare coagulation factor deficiencies should be individualized; leaves open the need for prospective trials to establish benefit.
The rare inherited coagulation factor deficiencies (deficiencies of factors I, II, V, VII, XI, XIII, combined FV + FVII deficiency, combined deficiency of the vitamin K dependent factors and von Willebrand disease type 3) have an aggregate prevalence of approximately 1:100,000. They may cause recurrent life or function threatening haemorrhage. In this article we review the available literature on long-term prophylaxis and, where possible, make recommendations on this important area.
No takes yet. Share an insight, caveat, or question.
Todd et al. (2009) conducted a review in Rare inherited coagulation factor deficiencies. Long-term prophylaxis was evaluated. Long-term prophylaxis for rare inherited coagulation factor deficiencies, which have an aggregate prevalence of approximately 1:100,000, is reviewed to provide clinical recommendations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: